Last updated on January 2019

Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit/Hyperactivity Disorder


Brief description of study

To evaluate the long-term safety of SPD489 administered as a daily morning dose (5, 10, 15, 20, and 30 mg/day) in preschool children diagnosed with Attention-deficit/Hyperactivity Disorder (ADHD). Participants will be enrolled into this study from antecedent study SPD489-211 (NCT02402166) or SPD489-347 (NCT03260205) (roll-over participants) or through direct enrollment (direct enrolled pariticpants).

Clinical Study Identifier: NCT02466386

Contact Investigators or Research Sites near you

Start Over

Paul Robbins

Coastal Carolina Research
Mount Pleasant, SC United States
1.13miles

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.